AstraZeneca announced a trial date has been set for patent litigation in the US District Court for the District of New Jersey against Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement of AstraZeneca's patent as a result of Teva's and Sandoz's filings of Abbreviated New Drug Applications (ANDAs).
Read more ...
Femara® helps protect against return of breast cancer
Women may reduce the risk of their breast cancer returning by starting treatment with Femara® (letrozole) anywhere from one to seven years after finishing tamoxifen therapy, according to a new analysis published today in the Journal of Clinical Oncology[1].
Read more ...
Nycomed intends to move chemical production to Indian joint venture
Nycomed and Cadila Healthcare have signed a letter agreement with the intent to amend their existing joint venture agreement to include the chemical production of active pharmaceutical ingredients (APIs) by the joint venture company Zydus Nycomed in India. Based on this agreement, Nycomed plans to transfer the current chemical production from the sites in Linz (Austria) and Singen (Germany) to the new joint venture within the next three to four years.
Read more ...
Baxter and its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs
Baxter International Inc. and The Baxter International Foundation, the philanthropic arm of Baxter, today announced their combined 2007 charitable giving, which focused on increasing access to healthcare, helping developing nations and countries in crisis, and addressing other critical community needs.
Read more ...
A successful 2007 paves the way for future of Nycomed
In 2007 Nycomed increased adjusted EBITDA by 31.0% compared to last year to a total of € 1,222.2 million. The strong performance was accompanied in the fourth quarter by major advancements in the US out-licensing efforts that materialised in early 2008. The full year results benefited from increased sales, especially from high-margin products as well as a significant reduction in costs.
Read more ...
Amgen Announces Update to U.S. Prescribing Information for Aranesp(R) and EPOGEN(R)
Amgen Inc. (NASDAQ:AMGN) announced the U.S. Food and Drug Administration (FDA) has approved updated safety information, including an updated boxed warning in the labeling information for the class of drugs known as erythropoiesis-stimulating agents (ESAs), including Aranesp(R) (darbepoetin alfa) and EPOGEN(R) (Epoetin alfa).
Read more ...
Pfizer Wins Challenge to Two Main U.S. Patents for Celebrex
Pfizer Inc announced today that the Court of Appeals for the Federal Circuit has upheld the two main U.S. patents covering Celebrex, the company's selective non-steroidal anti-inflammatory (NSAID) medicine used to treat pain and inflammation. The patents had been challenged by generic manufacturer Teva Pharmaceuticals USA.
Read more ...